137 results
Page 3 of 7
8-K
EX-1.1
e0g2tkvz0f
27 Apr 22
Agile Therapeutics Announces 1-FOR-40 Reverse Stock Split
7:21am
8-K
kccpt0nilplgbw
27 Apr 22
Agile Therapeutics Announces 1-FOR-40 Reverse Stock Split
7:21am
8-K
EX-99.1
b8gps
30 Mar 22
Agile Therapeutics Reports Fourth Quarter & Full Year 2021 Financial Results and Provides Corporate Update
4:19pm
8-K
EX-10.1
hpswc8pvpt7tfq
15 Mar 22
Agile Therapeutics Announces $4.85 Million Registered Direct Offering
5:03pm
8-K
EX-10.1
hjy7 nvyh
11 Mar 22
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-99.1
0285 q4hjd
10 Jan 22
Entry into a Material Definitive Agreement
8:05am
8-K
EX-1.1
lbuquucfkoxghv96z7yn
10 Jan 22
Entry into a Material Definitive Agreement
8:05am
8-K
EX-10.1
23ebitel s4vhtd95s4
10 Jan 22
Entry into a Material Definitive Agreement
8:05am
424B5
9r2 imgx7i8nctqx2
10 Jan 22
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
t97wzhee1svg
2 Nov 21
Agile Therapeutics Reports Third Quarter 2021 Financial Results
4:11pm
8-K
EX-1.1
aojua07 s6t
8 Oct 21
Agile Therapeutics Appoints Josephine Torrente to its Board of Directors
5:23pm
8-K
EX-99.1
3f5nl3b qhlk
4 Oct 21
Agile Therapeutics Announces Addition of Twirla® to a Preferred Drug Position on Medi-Cal Formulary
4:30pm